Disease, Disability, and Injury Prevention and Control, 17967 [E9-8947]
Download as PDF
rmajette on PRODPC74 with NOTICES
Federal Register / Vol. 74, No. 74 / Monday, April 20, 2009 / Notices
Agenda: To discuss the annual strategic
plan updating process and services and
supports activities.
Place:
In Person: National Institutes of Health,
William H. Natcher Conference Center, 45
Center Drive/Building 45, Conference Rooms
E1/E2, Bethesda Campus, Bethesda, MD
20892.
Videocast: https://videocast.nih.gov.
Contact Person: Ms. Lina Perez, Office of
Autism Research Coordination, Office of the
Director, National Institute of Mental Health,
NIH, 6001 Executive Boulevard, Bethesda,
MD 20892–9669, (301) 443–6040.
IACCpublicinquiries@mail.nih.gov.
Any member of the public interested in
presenting oral comments to the Committee
should notify the Contact Person listed on
this notice at least 10 days in advance of the
meeting. Interested individuals and
representatives of organizations should
submit a letter of intent, a brief description
of the organization represented, and a
written/electronic copy of the oral
presentation in advance of the meeting. Only
one representative of an organization will be
allowed to present oral comments and
presentations will be limited to a maximum
of five minutes. Both printed and electronic
copies are requested following the
presentation for the public record. In
addition, any interested person may submit
written comments to the Committee by
forwarding the statement to the Contact
Person listed on this notice. The statement
should include the name, address, telephone
number and when applicable, the business or
professional affiliation of the interested
person.
NIH has instituted stringent security
procedures for entrance onto the NIH
campus. All visitors must enter through the
NIH Gateway Center. This center combines
visitor parking, non-commercial vehicle
inspection and visitor ID processing, all in
one location. The NIH will process all
visitors in vehicles or as pedestrians. You
will be asked to submit to a vehicle or
personal inspection and will be asked to state
the purpose of your visit. Visitors over 15
years of age must provide a form of
government-issued ID such as a driver’s
license or passport. All visitors should be
prepared to have their personal belongings
inspected and to go through metal detection
inspection.
When driving to NIH, plan some extra time
to get through the security checkpoints. Be
aware that visitor parking lots on the NIH
campus can fill up quickly. The NIH campus
is also accessible via the metro Red Line,
Medical Center Station. The Natcher
Conference Center is a 5-minute walk from
the Medical Center Metro Station.
Additional NIH campus visitor information
is available at: https://www.nih.gov/about/
visitor/index.htm. Information about the
IACC and a registration link for this meeting
are available on the Web site: https://
www.iacc.hhs.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281, Scientist Development
Award, Scientist Development Award for
Clinicians, and Research Scientist Award;
VerDate Nov<24>2008
15:02 Apr 17, 2009
Jkt 217001
93.282, Mental Health National Research
Service Awards for Research Training,
National Institutes of Health, HHS)
Dated: April 13, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–9033 Filed 4–17–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control
Special Emphasis Panel: Pilot
Lifestyle Interventions for Pregestational
Diabetes or Gestational Diabetes,
Potential Extramural Project, PEP 2009–
R–02
Correction: This notice was published
in the Federal Register on March 25,
2009, Volume 74, Number 56, page
12873. The original notice was
published with an incorrect Potential
Extramural Project number.
Contact Person for More Information:
Linda Shelton, Public Health Analyst,
Coordinating Center for Health and
Information Service, Office of the
Director, CDC, 1600 Clifton Road NE.,
Mailstop E21, Atlanta, GA 30333.
Telephone (404) 498–1194.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Dated: April 9, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–8947 Filed 4–17–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0143]
Risk Evaluation and Mitigation
Strategies for Certain Opioid Drugs;
Notice of Public Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION: Notice of public meeting;
request for comments.
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
17967
SUMMARY: The Food and Drug
Administration (FDA) is announcing a
public meeting to obtain input on
developing Risk Evaluation and
Mitigation Strategies (REMS) for certain
opioid drugs. The REMS would be
intended to ensure that the benefits of
these drugs continue to outweigh
certain risks. The agency has long been
concerned about adverse events
associated with this class of drug and
has taken steps in cooperation with drug
manufacturers to address these risks.
We intend to use the agency’s REMS
authority under the Food and Drug
Administration Amendments Act of
2007 (FDAAA) to mitigate the risks of
these drugs. The purpose of the public
meeting is to receive information and
comments on this topic.
DATES: The public meeting will be held
on May 27 and 28, 2009, from 8 a.m. to
5 p.m. Register to attend the meeting by
May 15, 2009. See section III of this
document for information on how to
register or make an oral presentation at
the meeting. Written or electronic
comments will be accepted until June
30, 2009.
ADDRESSES: The public meeting will be
held at the Hilton Washington, DC
North/Gaithersburg Hotel, 620 Perry
Pkwy., Gaithersburg, MD 20877. Submit
written comments to the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061. Rockville, MD 20852.
Submit electronic comments to https://
www.regulations.gov. All comments
should be identified with the docket
number found in brackets in the
heading of this document. Transcripts of
the meeting will be available for review
at the Division of Dockets Management
and on the Internet at https://
www.regulations.gov approximately 30
days after the meeting.
FOR FURTHER INFORMATION CONTACT:
Theresa (Terry) Martin, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 6184,
Silver Spring, MD 20993–0002, 301–
796–3448, FAX: 301–847–8752, or Anne
Henig, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg 51, rm. 6176, Silver Spring,
MD 20993–0002, 301–796–3442, FAX:
301–847–8753, email:
OpioidREMS@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
FDAAA (Public Law 110–85) created
section 505–1 of the Federal Food, Drug,
and Cosmetic Act (the act) (21 U.S.C.
355–1). Under section 505–1 of the act,
E:\FR\FM\20APN1.SGM
20APN1
Agencies
[Federal Register Volume 74, Number 74 (Monday, April 20, 2009)]
[Notices]
[Page 17967]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-8947]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control
Special Emphasis Panel: Pilot Lifestyle Interventions for
Pregestational Diabetes or Gestational Diabetes, Potential Extramural
Project, PEP 2009-R-02
Correction: This notice was published in the Federal Register on
March 25, 2009, Volume 74, Number 56, page 12873. The original notice
was published with an incorrect Potential Extramural Project number.
Contact Person for More Information: Linda Shelton, Public Health
Analyst, Coordinating Center for Health and Information Service, Office
of the Director, CDC, 1600 Clifton Road NE., Mailstop E21, Atlanta, GA
30333. Telephone (404) 498-1194.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both CDC and the Agency for Toxic Substances and Disease Registry.
Dated: April 9, 2009.
Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E9-8947 Filed 4-17-09; 8:45 am]
BILLING CODE 4163-18-P